Sun Pharma is moving forward with a $12 billion offer for Organon & Co. This acquisition would be the largest for an Indian pharma company. Sun Pharma is finalizing financing for the deal. Organon specializes in women’s health. The company is also facing competition from other global consortiums. This move signifies Sun Pharma’s ambition to grow in innovative drug research.
Multi-asset allocation mutual funds: Nippon India, HDFC feature among SIP top performers and laggards
Systematic investment plans (SIPs) across major equity fund categories have delivered returns over the past two years even as most benchmark indices struggled during the